Jennifer Taubert compensation by year
JOHNSON & JOHNSON Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $796,154 | $884,615 | $938,077 | $1,008,462 | $1,130,000 | $1,192,308 | $1,220,308 |
| Bonus | $0 | $0 | $0 | $0 | — | $0 | $0 |
| Stock awards | $2,625,279 | $4,468,928 | $4,947,245 | $4,764,921 | $4,246,820 | $4,670,057 | $6,160,665 |
| Option awards | $1,200,004 | $1,499,997 | $1,713,005 | $1,859,958 | $1,799,992 | $2,129,987 | $2,430,013 |
| Non-equity incentive | $1,179,065 | $990,058 | $1,510,314 | $1,094,875 | $1,896,250 | $1,909,125 | $2,002,750 |
| Pension and deferred compensation | $1,237,000 | $1,642,000 | $1,067,411 | $0 | $1,844,000 | $1,226,000 | $2,126,364 |
| All other | $59,798 | $46,871 | $49,707 | $53,316 | $78,332 | $62,568 | $89,963 |
| Total | $7,097,300 | $9,532,469 | $10,225,759 | $8,781,532 | $10,995,394 | $11,190,045 | $14,030,063 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: JOHNSON & JOHNSON DEF 14A filed March 11, 2026, accession 0000200406-26-000063, and prior-year filings.
How this page was built: the JOHNSON & JOHNSON filed document, accession 0000200406-26-000063. Every figure is read from that document and cited to the page and table it appears in. Filed March 11, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 53,968 | $11,205,376 | — |
| RSU | 36,325 | $7,542,160 | — |
| RSU | 27,412 | $5,691,554 | — |
| RSU | 5,539 | $1,150,063 | — |
| RSU | 3,188 | $661,924 | — |
| RSU | 1,302 | $270,334 | — |
| Option | 91,324 | — | $151.41 |
| Option | 89,781 | — | $156.15 |
| Option | 82,127 | — | $164.62 |
| Option | 43,391 | — | $129.51 |
| Option | 43,712 | — | $115.67 |
| Option | 67,397 | — | $131.94 |
Per the Outstanding Equity Awards at Fiscal Year-End table in JOHNSON & JOHNSON's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed March 11, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-17 | Sale | — | 15,000 | $263.36 | 194,451 |
| 2026-08-17 | Exercise or conversion derivative | — | 15,000 | $0.00 | 28,712 |
| 2026-08-17 | Exercise or conversion | — | 15,000 | $115.67 | 209,451 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
JOHNSON & JOHNSON’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joaquin Duato | Chairman/CEO | $32,758,111 |
| Joseph Wolk | EVP, CFO | $14,405,442 |
| Jennifer Taubert · this page | EVP, WWC Innovative Medicine | $14,030,063 |
| John Reed | EVP, Innovative Medicine, R&D | $12,214,062 |
| Tim Schmid | EVP, WWC, MedTech | $9,336,765 |
Jennifer Taubert's compensation dossier, JOHNSON & JOHNSON
You have read Jennifer Taubert's totals and holdings. The dossier adds each equity grant JOHNSON & JOHNSON disclosed for Jennifer Taubert and JOHNSON & JOHNSON's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full JOHNSON & JOHNSON compensation record
free company briefThis page is one person within JOHNSON & JOHNSON's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the JOHNSON & JOHNSON proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order JOHNSON & JOHNSON's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are JOHNSON & JOHNSON's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.